EphA3 Maintains Tumorigenicity and Is a Therapeutic Target in Glioblastoma Multiforme

Overview of attention for article published in Cancer Cell, February 2013

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (97th percentile)

So far, Altmetric has seen 13 news stories from 13 outlets.

| Spoke Humanigen Announces Completion of Enrollment in Phase 1 Study of Ifabotuzumab in Glioblastoma Multiforme BURLINGAME…

BURLINGAME, Calif.--(Business Wire)-- Humanigen, Inc. (NASDAQ: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company…

Humanigen, Inc. (NASDAQ: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company developing its portfolio of clinical…

- Humanigen, Inc. (NASDAQ: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company developing its portfolio of clinical…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 9 additional news stories.